Press release
Thalassemia Drugs Market Size, Latest Analysis, Share And Forecast 2033
Thalassemia Drugs Market
The Business Research Company offers in-depth market insights through Thalassemia Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The thalassemia drugs market size has grown rapidly in recent years. It will grow from $2.07 billion in 2023 to $2.3 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing prevalence of thalassemia, genetic predisposition and prevalence, advances in healthcare infrastructure, growing awareness of thalassemia, improvements in diagnostic capabilities.
The thalassemia drugs market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to growing gene therapies for thalassemia, growing demand for targeted and personalized medicine, increased investments in rare disease drug development, rise in healthcare expenditure, global initiatives for thalassemia awareness. Major trends in the forecast period include personalized treatment regimens, integration of digital health solutions in thalassemia management, development of research on curative therapies, development of combination drug therapies, expansion of patient support programs.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12213&type=smp
Market Segmentation:
The thalassemia drugs market covered in this report is segmented -
1) By Type: Alpha Thalassemia Drugs, Beta Thalassemia Drugs
2) By Treatment Type: Iron Chelation Therapy, Other Treatments
3) By Distribution Channel: Hospital Pharmacies, Online Providers, Drug Stores And Retail Pharmacies
Major Driver - Thalassemia Market Growth Fueled By Increased R&D Expenditure In The Healthcare Sector
Rising R&D expenditure is expected to boost the thalassemia market going forward. R&D investment can be defined as the expenses undertaken by a company for developing, designing, and enhancing its offerings. Increased expenditure can boost innovation and productivity in designing and formulating innovative drugs for the treatment of thalassemia. For instance, according to a report published by the European Federation of Pharmaceutical Industries and Associations, a Belgium-based pharmaceuticals-based trade association, in 2021 European health industries invested about 41.5 billion euros ($44.47 billion) for R&D expenditure, an increase compared to 39.65 billion euros ($42.49 billion) in 2020. Therefore, rising R&D expenditure is driving thalassemia market.
Competitive Landscape:
Major companies operating in the thalassemia drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., Fresenius Kabi AG, Bristol Myers Squibb Co., Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Incyte Corporation, Chiesi Farmaceutici S.p.A., Cipla Ltd., Panacea Biotec Ltd., Ionis Pharmaceuticals Inc., Alvogen Inc., Apotex Inc., Acceleron Pharma Inc., Alnylam Pharmaceuticals Inc., Shanghai Bioray Laboratory Inc., La Jolla Pharmaceutical Company, Editas Medicine Inc., Agios Pharmaceuticals Inc., Bluebird Bio Inc., Gamida Cell Ltd., CRISPR Therapeutics AG
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/thalassemia-drugs-global-market-report
Top Trend - Groundbreaking Cell-Based Gene Therapy For Beta-Thalassemia Treatment
Product innovation is a key trend gaining popularity in the thalassemia drug market. Major companies operating in the thalassemia drug market are developing innovative products to sustain their position in the market. For instance, in August 2022, Bluebird Bio Inc., a US-based biotechnology company, approved Zynteglo (betibeglogene autotemcel) to treat beta-thalassemia. Zynteglo is the first cell-based, one-time gene therapy administered as a single dose. It is prepared by using the patient's genetically modified cells to produce functional beta-globin.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Thalassemia Drugs Market Characteristics
3. Thalassemia Drugs Market Trends And Strategies
4. Thalassemia Drugs Market - Macro Economic Scenario
5. Thalassemia Drugs Market Size And Growth
…..
27. Thalassemia Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thalassemia Drugs Market Size, Latest Analysis, Share And Forecast 2033 here
News-ID: 3431267 • Views: …
More Releases from The Business research company
Exploring the Global Gas Turbine Services Market: A Comprehensive Overview
The gas turbine services market size has grown rapidly in recent years. It will grow from $26.82 billion in 2023 to $29.52 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to aging gas turbine fleet, increased energy demand, rise in industrialization, focus on efficiency, stringent environmental regulations.
The gas turbine services market size is expected to…
Exploring the Global Form-Fill-Seal Equipment Market: A Comprehensive Overview
The form-fill-seal equipment market size has grown strongly in recent years. It will grow from $16.87 billion in 2023 to $17.95 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to industry regulations, cost efficiency, market competition, product diversification, globalization.
The form-fill-seal equipment market size is expected to see strong growth in the next few years. It…
Exploring the Global Flexible Foam Market: A Comprehensive Overview
The flexible foam market size has grown strongly in recent years. It will grow from $50.76 billion in 2023 to $54.32 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to demand from consumer electronics sector, expansion of packaging applications, shift towards comfortable furniture and bedding, expansion of automotive applications, demand for insulation in construction.
The flexible…
Exploring the Global Fall Protection Equipment Market: A Comprehensive Overview
The fall protection equipment market size has grown strongly in recent years. It will grow from $3.12 billion in 2023 to $3.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to economic development, risk management strategies, workplace safety regulations, industrialization and construction boom, urbanization and infrastructure projects.
The fall protection equipment market size is expected to…
More Releases for Thalassemia
Thalassemia Market to Witness Growth Acceleration | SG Pharma Pvt. Lmt.
The Thalassemia Market Report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each region and country involved in the study. Furthermore, It studies the market essential sectors such as top participants, expansion strategies, business models, and other industry features to improve the current strategy of key players. Facts and data are presented in reports using diagrams, graphs, pie charts, and other pictorial representations.…
Global Thalassemia Market Size – Forecast to 2026
The findings reviewed by GME stated that the Global Thalassemia Market will expand with a CAGR value of 10.2 percent from 2021 to 2026. Several drivers are likely to accelerate the thalassemia market further, including an increasing occurrence of thalassemia, growing public awareness, expanding expenditure in research & development, and the growing need for improved curative gene therapy.
Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and…
Thalassemia Treatment Market is driven by increase in number of altered thalasse …
Thalassemia Treatment Market - Snapshot
The global thalassemia treatment market is driven by increase in number of altered thalassemia genes across the globe. The global market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026 to reach US$ 1,639.6 Mn by 2026. The global market is witnessing high growth owing to increase in blood transfusion and chelation therapy…
Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” report studies Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin.…
Thalassemia - Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow…
Thalassemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Thalassemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms…
